885698-70-4

Basic information

• Product Name: 1-Acetyl-4-bromo-1H-indazole
• Synonyms: 1-Acetyl-4-bromo-1H-indazole;Ethanone, 1-(4-broMo-1H-indazol-1-yl)-;1-(4-Bromoindazol-1-yl)ethanone;1-(4-Bromo-1H-indazol-1-yl)
• CAS NO: 885698-70-4
• Molecular Formula: C₉H₇BrN₂O
• Molecular Weight: 239.06868
• Mol File: 885698-70-4.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Acetyl-4-bromo-1H-indazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Acetyl-4-bromo-1H-indazole(885698-70-4)
• EPA Substance Registry System: 1-Acetyl-4-bromo-1H-indazole(885698-70-4)

Safety Data

• Hazardous Substances Data: 885698-70-4(Hazardous Substances Data)

Usage

General Description

1-Acetyl-4-bromo-1H-indazole is a chemical compound with the molecular formula C10H8BrNO. It is a derivative of indazole, a heterocyclic aromatic organic compound. This chemical contains a bromine atom and an acetyl group, making it a halogenated indazole compound. It is used in the pharmaceutical industry as an intermediate for the synthesis of various pharmaceutical compounds. 1-Acetyl-4-bromo-1H-indazole may have potential applications in medicinal chemistry and drug discovery due to its structural features and potential biological activities. However, further research is needed to fully understand its properties and potential uses in medicine.

Upstream product

• 55289-36-6 3-bromo-2-methylaniline 
• 108-24-7 acetic anhydride 
• 127-08-2 potassium acetate 
• 110-46-3 isopentyl nitrite 

Downstream Products

• 1158680-96-6 1-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)indazol-1-yl]ethanone 
• 271-44-3 benzimidazole 
• 885618-33-7 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole 
• 186407-74-9 4-bromoindazole 

Relevant articles and documents

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

DIOXINO-AND OXAZIN-[2,3-D]PYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Dioxino-and oxazin-[2,3-d]pyrimidine PI3K inhibitor compounds of Formula I with anti-cancer activity, anti-in-flammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are de-scribed. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions.

TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti- inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.